These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

316 related articles for article (PubMed ID: 24623281)

  • 21. Immunotherapy in pediatric acute lymphoblastic leukemia.
    Inaba H; Pui CH
    Cancer Metastasis Rev; 2019 Dec; 38(4):595-610. PubMed ID: 31811553
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Epratuzumab and Blinatumomab as Therapeutic Antibodies for Treatment of Pediatric Acute Lymphoblastic Leukemia: Current Status and Future Perspectives.
    Franca R; Favretto D; Granzotto M; Decorti G; Rabusin M; Stocco G
    Curr Med Chem; 2017; 24(11):1050-1065. PubMed ID: 28088906
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Humoral and cellular immunotherapy in ALL in children, adolescents, and young adults.
    Hochberg J; El-Mallawany NK; Cairo MS
    Clin Lymphoma Myeloma Leuk; 2014 Sep; 14 Suppl():S6-13. PubMed ID: 25486958
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Inotuzumab ozogamicin in the treatment of relapsed/refractory acute B cell lymphoblastic leukemia.
    Uy N; Nadeau M; Stahl M; Zeidan AM
    J Blood Med; 2018; 9():67-74. PubMed ID: 29713210
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Targeted therapy with monoclonal antibodies in acute lymphoblastic leukemia.
    Hoelzer D
    Curr Opin Oncol; 2013 Nov; 25(6):701-6. PubMed ID: 24097105
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Inotuzumab ozogamicin for the treatment of patients with acute lymphocytic leukemia.
    Choudhry A; O'Brien SM
    Drugs Today (Barc); 2017 Dec; 53(12):653-665. PubMed ID: 29517084
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Novel immunotherapies in lymphoid malignancies.
    Batlevi CL; Matsuki E; Brentjens RJ; Younes A
    Nat Rev Clin Oncol; 2016 Jan; 13(1):25-40. PubMed ID: 26525683
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Using immunotherapy and novel trial designs to optimise front-line therapy in adult acute lymphoblastic leukaemia: breaking with the traditions of the past.
    Short NJ; Kantarjian H
    Lancet Haematol; 2023 May; 10(5):e382-e388. PubMed ID: 37003279
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Novel therapeutic strategies in adult acute lymphoblastic leukemia--a focus on emerging monoclonal antibodies.
    Daver N; O'Brien S
    Curr Hematol Malig Rep; 2013 Jun; 8(2):123-31. PubMed ID: 23539383
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Treatment of adult acute lymphoblastic leukemia with inotuzumab ozogamicin.
    Paul S; Rausch CR; Kantarjian H; Jabbour EJ
    Future Oncol; 2017 Oct; 13(25):2233-2242. PubMed ID: 28776425
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Should immunologic strategies be incorporated into frontline ALL therapy?
    Rank CU; Stock W
    Best Pract Res Clin Haematol; 2018 Dec; 31(4):367-372. PubMed ID: 30466749
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Direct CNS administration of rituximab and epratuzumab in a pediatric patient with relapsed refractory CNS B-cell acute lymphoblastic leukemia.
    McClane J; Chawla A; Welch JJG
    Pediatr Blood Cancer; 2022 Jun; 69(6):e29664. PubMed ID: 35293685
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immunotherapy for the Treatment of Acute Lymphoblastic Leukemia.
    Barsan V; Ramakrishna S; Davis KL
    Curr Oncol Rep; 2020 Jan; 22(2):11. PubMed ID: 31997022
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Targeting CD22 in B-cell malignancies: current status and clinical outlook.
    Sullivan-Chang L; O'Donnell RT; Tuscano JM
    BioDrugs; 2013 Aug; 27(4):293-304. PubMed ID: 23696252
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Inotuzumab ozogamicin in relapsed B-cell acute lymphoblastic leukemia.
    Thota S; Advani A
    Eur J Haematol; 2017 May; 98(5):425-434. PubMed ID: 28152223
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Inotuzumab Ozogamicin: First Global Approval.
    Lamb YN
    Drugs; 2017 Sep; 77(14):1603-1610. PubMed ID: 28819740
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Chemoimmunotherapy with inotuzumab ozogamicin combined with mini-hyper-CVD, with or without blinatumomab, is highly effective in patients with Philadelphia chromosome-negative acute lymphoblastic leukemia in first salvage.
    Jabbour E; Sasaki K; Ravandi F; Huang X; Short NJ; Khouri M; Kebriaei P; Burger J; Khoury J; Jorgensen J; Jain N; Konopleva M; Garcia-Manero G; Kadia T; Cortes J; Jacob J; Montalbano K; Garris R; O'Brien S; Kantarjian HM
    Cancer; 2018 Oct; 124(20):4044-4055. PubMed ID: 30307611
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [ALL in adult patients: Contribution and limits of pediatric management].
    Rabian F; Boissel N
    Bull Cancer; 2021 Feb; 108(2):187-197. PubMed ID: 32981690
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Current status of antibody therapy in ALL.
    Ai J; Advani A
    Br J Haematol; 2015 Feb; 168(4):471-80. PubMed ID: 25382151
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Novel Therapies in the Treatment of Adult Acute Lymphoblastic Leukemia.
    Gavralidis A; Brunner AM
    Curr Hematol Malig Rep; 2020 Aug; 15(4):294-304. PubMed ID: 32445026
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.